Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Aripiprazole Adjunctive Therapy in MDD
NCT00882362Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2009
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 52 weeks. Started Mar 2009; status: completed.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00882362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882362.